CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Zuellig Pharma

Imelda Rillon, Corporate Head of Quality & HSSE

Quality Assurance: Navigating the Escalating Compliance Complexities

Imelda Rillon

Imelda Rillon

Compliance Quality Strategist

With the escalating complexity of compliance requirements and aggressive business transformation initiatives in the pharmaceutical industry, Quality Assurance is proven to be a business imperative to ensure competitiveness and success.


At Zuellig Pharma, the largest health services group in Asia, we remain focused on our mission of “Making Healthcare More Accessible”. Ensuring quality of products is a tall order in a complex supply chain network, hence, our vision transcends from accessibility to ensuring patients receive medicines of the right quality and efficacy.


We found these four factors essential in establishing Quality Assurance:


First, laying the foundation. It is important to build a robust Quality Management System which is the bedrock of any process execution. We spend significant resource in creating and maintaining a robust QMS. Our governance systems and standards are aligned to the requirements of international regulators such as the EMA and MHRA in Europe, USFDA, WHO, PIC/s and ICH as well as industry bodies such us the PDA, ISPE and ISTA. Industry trends and upcoming requirements are evaluated based on their impact to our processes and embedded into our corporate QMS. Our business units across Asia then create their standard operating procedures tightly aligned to the corporate QMS and compliant to local regulations. These SOPs are their working documents for process execution.


Second, creating a masterplan. In 2015, we started developing our Quality Roadmap spanning across a 5-year horizon and is built around three strategic pillars of People, Process and Technology. This roadmap is reviewed and updated annually keeping us on-track of our quality objectives. In 2026, we aim to be Recognized Quality Experts for Industry & Geography (People), our QMS Recognized as the Industry Reference (Process) and our Core Quality Documentation Digitalized (Technology).


"In a rapidly changing business landscape, Quality Assurance remains the anchor, ensuring procedures and strategies offer reliability and efficiency, and Zuellig Pharma continues to exploit Quality as a competitive advantage, developing customer trust and positioning our organisation for success."


Third, nurturing people. We create safe avenues for our people to share their thoughts and needs. From an informal shopfloor huddle and weekly team catchup to the more formal townhalls and organization-wide employee opinion survey, leaders effectively listen. Employee feedbacks are evaluated, action plans developed, implemented and communicated to the people.and organization-wide employee opinion survey, leaders effectively listen. Employee feedbacks are evaluated, action plans developed, implemented and communicated to the people.In Quality Department we have established a regular Individual Development Plan discussion with staff to understand their career aspirations and how the organization can provide training, coaching and other interventions to ensure they are developing towards their goal and making an impact to the overall objective of the organization. Non-QA functions are made part of our Quality Assurance Competency Certification Program, a 5-tier certification process composed of quality learning modules and project management assignments to create awareness, interest and ownership of quality across the organization.


Fourth, embarking in technology. Key to Quality Assurance is making risk-based decisions. An inhouse-application, eQMS, was developed automating key quality systems such as Deviation & CAPA, Documentation, Audit, Change and Risk management. eQMS is an enabler to our Quality 4.0 aspiration enabling predictive analytics and in the future prescriptive and cognitive for enhanced quality risk management. Business transformation initiatives employ a Quality by Design approach where Quality team is involved at project conceptualization stage to ensure compliance requirements are met.


In the rapidly changing business landscape, Quality Assurance remain to be the anchor ensuring processes and strategies deliver reliability and efficiency. Zuellig Pharma continue to leverage on Quality as our competitive advantage building customer trust and positioning our organization for success.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Enterprise quality frameworks in life sciences are being reshaped by the growing demand for integrated regulatory control across distributed operations. This perspective underlines how regional quality leadership is becoming a central enabler of risk mitigation and operational consistency in global pharma networks.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/imelda-rillon-nwid-3294.html